Teladoc Inc (NYSE:TDOC) shares dropped 0% during trading on Friday . The company traded as low as $38.65 and last traded at $39.15. Approximately 747,389 shares were traded during mid-day trading, a decline of 32% from the average daily volume of 1,103,035 shares. The stock had previously closed at $39.15.
TDOC has been the topic of a number of research analyst reports. ValuEngine raised Teladoc from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Citigroup initiated coverage on Teladoc in a report on Thursday, January 4th. They issued a “buy” rating on the stock. KeyCorp reissued a “buy” rating and issued a $41.00 price target on shares of Teladoc in a report on Wednesday, January 10th. Jefferies Group initiated coverage on Teladoc in a report on Friday, January 26th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, Canaccord Genuity boosted their price target on Teladoc from $42.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $41.67.
The firm has a market capitalization of $2,555.48, a PE ratio of -23.73 and a beta of 0.36. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.87 and a quick ratio of 3.87.
Teladoc (NYSE:TDOC) last issued its quarterly earnings data on Tuesday, February 27th. The health services provider reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.10). The firm had revenue of $77.14 million for the quarter, compared to analysts’ expectations of $76.14 million. Teladoc had a negative return on equity of 20.95% and a negative net margin of 45.77%. analysts predict that Teladoc Inc will post -1.37 EPS for the current year.
In other news, insider Adam C. Vandervoort sold 47,123 shares of the company’s stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $39.36, for a total transaction of $1,854,761.28. Following the sale, the insider now directly owns 19,338 shares of the company’s stock, valued at approximately $761,143.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Andrew Turitz sold 19,245 shares of the company’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $39.25, for a total value of $755,366.25. Following the sale, the senior vice president now directly owns 16,700 shares in the company, valued at $655,475. The disclosure for this sale can be found here. Insiders have sold a total of 364,494 shares of company stock worth $14,665,947 over the last ninety days. Insiders own 4.47% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of TDOC. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Teladoc by 63.7% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 9,546 shares of the health services provider’s stock worth $316,000 after acquiring an additional 3,714 shares in the last quarter. New York State Common Retirement Fund increased its position in shares of Teladoc by 33.2% during the 3rd quarter. New York State Common Retirement Fund now owns 90,513 shares of the health services provider’s stock valued at $3,001,000 after purchasing an additional 22,554 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Teladoc by 2.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 285,788 shares of the health services provider’s stock valued at $9,474,000 after purchasing an additional 6,396 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of Teladoc by 7.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 48,941 shares of the health services provider’s stock valued at $1,622,000 after purchasing an additional 3,442 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its position in shares of Teladoc by 119.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 200,848 shares of the health services provider’s stock valued at $6,658,000 after purchasing an additional 109,373 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/04/08/teladoc-tdoc-trading-down-0.html.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.